Navigation Links
Experiment aboard shuttle Atlantis will test novel therapy to build bone during space travel
Date:7/6/2011

BOSTON Astronauts lose a significant amount of bone mass during space travel and with long duration flights there is concern that this bone loss could lead to an increased risk of fractures. When the final mission of NASA's 30-year Space Shuttle program is launched on July 8, an animal experiment to test a novel therapy to increase bone mass will be on board.

Led by a consortium of scientists from Beth Israel Deaconess Medical Center (BIDMC), Amgen, Inc., UCB, BioServe Space Technologies and the University of North Carolina, and funded by NASA's Ames Research Center, the research will not only address a serious problem that affects astronauts who spend weeks and months in a low-gravity environment, but may also yield novel insights into the prevention and treatment of skeletal fragility among patients on earth who are less active due to aging or illness.

"Mechanical loading is required to maintain musculoskeletal health," explains Co-Principal Investigator Mary Bouxsein, PhD, a scientist in BIDMC's Center for Advanced Orthopaedic Studies and Assistant Professor of Orthopaedic Surgery at Harvard Medical School.

"On earth, our bones experience mechanical forces from being pushed and pulled by muscles that work against gravity to keep us upright and moving around, as well as from the impact of our body weight against the ground," she explains. "These forces are much lower in micro-gravity environments and, as a result, the rate of bone loss among astronauts is about 10 times greater than that seen in postmenopausal women. So, while this research is designed to better understand and prevent skeletal fragility among astronauts, it may also tell us a great deal about the future potential of this novel therapy to improve bone strength here on earth, in both older persons and in individuals with reduced physical activity due to various clinical conditions, such as stroke, spinal cord injury or cerebral palsy."

NASA's Commercial Biomedical Test Module (CBTM-3) experiment will examine whether the use of an antibody that blocks the action of the protein sclerostin can lead to gains in bone mass and thereby prevent skeletal deterioration. (The sclerostin molecule is a potent inhibitor of bone formation that is produced by osteocytes, bone cells which form a "nerve-like" network that enable the skeleton to "feel" and respond to mechanical strain.)

"This proof-of-principle study will enhance our understanding of the science behind the sclerostin antibody and arm us with important research to support potential future therapeutic applications in both astronauts and patients suffering from bone loss," notes Amgen Scientific Executive Director Chris Paszty, PhD.

Thirty mice will be flown in space, with half of the animals given a preflight injection of the sclerostin antibody and the remaining mice receiving a placebo. After the flight lands (following 12 days in space), various aspects of the structure, composition, strength and cell and molecular nature of the bones from the flight and ground-based control mice will be analyzed.

"When the mice come back from space, we hope to learn what the effects of microgravity are on the skeleton and on the muscle," explains Bouxsein. "We also want to find out if this new type of therapy will be able to counteract those profound effects and actually promote bone gain in a microgravity environment.

"One in two women and one in five men over age 50 will suffer a fracture resulting from osteoporosis [and bone loss] during their remaining lifetime," she adds. "These fractures have profound personal and societal consequences. With the increasing age of the population there is urgent need to develop bone-building therapies to prevent this type of potentially debilitating injury."


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related medicine news :

1. Experimental Drug Bests Chemo in Non-Small Cell Lung Cancer Study
2. Experimental Vaccine Seems to Cure Prostate Cancer in Mice
3. ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients
4. Ex-Dallas Maverick survives rare form of leukemia thanks to experimental drug treatment
5. Experimental treatment offers relief from painful prostate condition
6. Christos Mantzoros honored by Federation of the American Societies for Experimental Biology
7. Experimental Test May Warn of Premature Births
8. Experts at Experimental Biology examine dietary cholesterol, egg intake and heart disease risk
9. Experimental Weight-Loss Drug Seems to Work: Study
10. Experimental drug achieves unprecedented weight loss
11. Science at a glance: Symposia, research and special events at Experimental Biology 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... Sabah Shah MD, MBA has joined the Retina ... of New York was founded by James M. Maisel, MD and has been providing tertiary ... has always followed a legacy of surpassing expectations amongst her peers. Growing up in ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Surgical Facial Rejuvenation" at the 2016 Anti-Aging & Beauty Awards at The ... The Aesthetic & Anti-aging Medicine European Congress (AMEC) brings together the industry’s ...
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in New York City, with long-time partners The Paul Foundation, on November 10, ...
(Date:12/4/2016)... ... 03, 2016 , ... Penrose Senior Care Auditors® was announced ... evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and Banquet ... for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, commitment ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges on regular brushing of ... optimal results. This important necessity inspired an inventor from Las Vegas, Nev., to design ... that people break or avoid bad techniques of brushing the teeth in order to ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Israel , December 5, 2016 ... identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase ... BL-8040, the Company,s leading oncology platform at the ongoing 58th ... San Diego, California . ... , , ...
(Date:12/5/2016)... Taiwan , Dec. 5, 2016 ... non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) ... profile of ropeginterferon alfa-2b versus HU AOP ... follow-up trial CONTINUATION-PV to obtain European marketing authorization in the ... data to the FDA as it seeks approval for commercialization ...
(Date:12/4/2016)... --  Pairnomix, LLC, a genetic research company and member ... White House, today announced that findings from its first case ... therapies for a patient with epileptic encephalopathy caused by a ... the 70 th Annual Meeting of the American ... December 2-6, 2016.  Pairnomix, unique process involves creating ...
Breaking Medicine Technology: